Related Experiment Video
Updated: May 31, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
Published on: February 8, 2022
Device closure of atrial septal defect: medium-term outcome with special reference to complications
Masood Sadiq1, Tehmina Kazmi, Asif U Rehman
1Department of Paediatric Cardiology, The Children's Hospital, Ferozepur Road, Lahore, Pakistan. drmasoodsadiq@hotmail.com
Insights
Device closure for secundum atrial septal defects is safe and effective long-term. Key complications like embolisation and residual shunts are linked to specific anatomical factors, while aortic regurgitation risk remains low.
Area of Science:
- Cardiology
- Interventional Cardiology
- Congenital Heart Disease
Background:
- Concerns exist regarding device closure of secundum atrial septal defects (ASD), particularly regarding erosions and aortic regurgitation.
- Transcatheter device closure has become a common alternative to surgical repair for ASD.
Purpose of the Study:
- To evaluate the medium-term outcomes of transcatheter device closure for secundum ASD.
- To specifically assess the incidence of complications such as erosions and aortic regurgitation.
Main Methods:
- 205 patients with secundum ASD underwent transcatheter closure using the Amplatzer Septal Occluder between 1999 and 2009.
- Medium-term follow-up data was available for 176 patients (88%).
Main Results:
- Successful device closure was achieved in 98% of patients.
- Complications included device embolisation (associated with short inferior caval vein margin), residual shunts (associated with short superior caval vein margin), and mild aortic regurgitation (linked to a high device-to-defect ratio).
- No erosions, late embolisation, or thromboembolism were observed.
Conclusions:
- Transcatheter device closure of secundum ASD with the Amplatzer device is safe and effective in the medium term.
- Specific anatomical features predict risks of embolisation and residual shunts.
- The risk of aortic regurgitation is low and predictable based on device selection.
Background:
There are concerns over the outcome of device closure of secundum atrial septal defect with special reference to erosions and aortic regurgitation.
Aim:
To assess the medium-term outcome of device closure of atrial septal defects with special reference to complications.
Methods:
A total of 205 patients with secundum atrial septal defects underwent transcatheter closure from October, 1999 to April, 2009. The median age was 18 (1.4-55) years. Amplatzer Septal Occluder was used in all the patients. Medium-term follow-up was available in 176 of 200 (88%) patients.
Results:
Device closure was successful in 200 out of 205 (98%) patients. The device embolised in four patients and was associated with short inferior caval vein margin (p = 0.003). Balloon sizing in 71 patients (35%) resulted in implantation of a larger device (p = 0.002). Early complications included pericardial effusion, 2:1 heart block, and infective endocarditis (1 patient each). There were eight patients who reported migraine (3.9%). At median follow-up of 5.8 (0.6-10.3) years, complete closure occurred in 197 out of 200 patients. Short superior caval vein margin was associated with a residual shunt (p < 0.001). There were two patients who developed mild aortic regurgitation (1%), which correlated with a device-to-defect ratio of >1.3:1 (p = 0.001). There were no erosions, late embolisation, or thromboembolism. Atrial fibrillation occurred in three adults (1.5%).
Conclusions:
Device closure of secundum atrial septal defects using Amplatzer Septal Occluder is safe and effective in the medium term. Short inferior caval vein margin correlates with increased risk of embolisation and short superior caval vein margin with a residual shunt. The risk of developing aortic regurgitation is low and correlates with increased device-to-defect ratio.
Related Concept Videos
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Aneurysm III: Interprofessional Care
Aortic Regurgitation III: Medical Management
Cardiomyopathy V: Interprofessional Care
Endocarditis III: Medical Management

